938 results on '"Flannery, Brendan"'
Search Results
2. Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
3. Risk for Infection in Humans after Exposure to Birds Infected with Highly Pathogenic Avian Influenza A(H5N1) Virus, United States, 2022
4. Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March-November 2020
5. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines
6. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness--United States
7. US Public Health Preparedness and Response to Highly Pathogenic Avian Influenza A(H5N1) Viruses
8. Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period
9. Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged
10. Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022.
11. Antibody Response to Symptomatic Infection With SARS‐CoV‐2 Omicron Variant Viruses, December 2021–June 2022.
12. Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020
13. Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities — United States, July 2020
14. Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020–February 2021
15. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023
16. Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020
17. Vaccine Effectiveness Against Pediatric Influenza-A–Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022–2023 Season: VISION Network.
18. Differences between Frequentist and Bayesian inference in routine surveillance for influenza vaccine effectiveness: a test-negative case-control study
19. Communicating the Value of Influenza Vaccines to Patients: Translating Vaccine Effectiveness to Acceptance
20. 1789. Comparison of influenza vaccine effectiveness estimates from the US Influenza Vaccine Effectiveness Network and Electronic Health Record Source Population Data, 2021-2022
21. Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021—June 2022
22. Vaccine Effectiveness Against Pediatric Influenza-A–Associated Urgent Care, Emergency Department, and Hospital Encounters During the 2022–2023 Season: VISION Network
23. Influenza Antiviral Shortages Reported by State and Territorial Public Health Officials, 2022-2023
24. Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022
25. Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019
26. Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
27. Paid Leave and Access to Telework as Work Attendance Determinants during Acute Respiratory Illness, United States, 2017-2018
28. Vaccination history as a confounder of studies of influenza vaccine effectiveness
29. Early and Increased Influenza Activity Among Children--Tennessee, 2022-23 Influenza Season
30. Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period
31. Work Attendance during Acute Respiratory Illness Before and During the COVID-19 Pandemic, United States, 2018-2022
32. Influence of Birth Cohort on Effectiveness of 2015–2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States
33. Kinetics of Serological Responses in Critically Ill Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011
34. Influenza Antiviral Prescribing for Outpatients With an Acute Respiratory Illness and at High Risk for Influenza-Associated Complications During 5 Influenza Seasons—United States, 2011–2016
35. Update : Influenza Activity — United States, October 1, 2017–February 3, 2018
36. Interim Estimates of 2017–18 Seasonal Influenza Vaccine Effectiveness — United States, February 2018
37. Update : Influenza Activity — United States, October 1–November 25, 2017
38. Influenza vaccine effectiveness in older adults compared with younger adults over five seasons
39. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013–2014 season
40. An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children
41. Burden of medically attended influenza infection and cases averted by vaccination – United States, 2013/14 through 2015/16 influenza seasons
42. Perception of Local COVID-19 Transmission and Use of Preventive Behaviors Among Adults with Recent SARS-CoV-2 Infection--Illinois and Michigan, June 1-July 31, 2022
43. Respiratory syncytial virus hospitalization in middle-aged and older adults
44. Prior-Season Vaccination and Risk of Influenza During the 2014–2015 Season in the United States
45. Update : Influenza Activity in the United States During the 2016–17 Season and Composition of the 2017–18 Influenza Vaccine
46. Intraseason Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011–2012 Through 2014–2015
47. Interim Estimates of 2016–17 Seasonal Influenza Vaccine Effectiveness — United States, February 2017
48. A randomized controlled trial to compare immunogenicity to cell-based vs. live-attenuated influenza vaccines in children
49. Risk factors for infection with influenza A(H3N2) virus on a US university campus, October–November 2021
50. Immunogenicity of High-Dose Egg-Based, Recombinant, and Cell Culture-Based Influenza Vaccines Compared to Standard-Dose Egg-Based Influenza Vaccine among Healthcare Personnel Aged 18-65 Years in 2019-2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.